GWAS on family history of Alzheimer's disease.
Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, Davies G, Ritchie CW, Gale CR, Starr JM, Goate AM, Porteous DJ, Yang J, Evans KL, Deary IJ, Wray NR, Visscher PM. · 2018
Read GWAS on family history of Alzheimer's disease. by Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, Davies G, Ritchie CW, Gale CR, Starr JM, Goate AM, Porteous DJ, Yang J, Evans KL, Deary IJ, Wray NR, Visscher PM. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5959890.txt.
Introduction
Marioni and co-authors run a genome-wide association study using family history of Alzheimer's disease. Their study appeared in Translational Psychiatry. The team used self-reported parental history in UK Biobank. That covered 314,278 participants. They asked whether such reports can stand in for real cases. The answer was yes for genetic study purposes. Meta-analysis with consortium data widened the search further.
Three new Alzheimer's-linked loci turned up, they report. The genes include ADAM10, BCKDK/KAT8, and ACE. Gene-based tests flagged the drug target VKORC1 as well. Signals near TOMM40 may work through gene expression and methylation. Some loci hold targets already used in other diseases.
Catalog record
| CREATOR | Marioni RE, Harris SE, Zhang Q, McRae AF, Hagenaars SP, Hill WD, Davies G, Ritchie CW, Gale CR, Starr JM, Goate AM, Porteous DJ, Yang J, Evans KL, Deary IJ, Wray NR, Visscher PM. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
GWAS on family history of Alzheimer’s disease By Riccardo E. Marioni, Sarah E. Harris, Qian Zhang, Allan F. McRae, Saskia P. Hagenaars, W. David Hill, Gail Davies, Craig W. Ritchie, Catharine R. Gale, John M. Starr, Alison M. Goate, David J. Porteous Published in: Translational Psychiatry DOI: 10.1038/s41398-018-0150-6 ABSTRACT Alzheimer’s disease (AD) is a public health priority for the 21st century. Risk reduction currently revolves around lifestyle changes with much research trying to elucidate the biological underpinnings. We show that self-report of parental history of Alzheimer’s dementia for case ascertainment in a genome-wide association study of 314,278 participants from UK Biobank (27,696 maternal cases, 14,338 paternal cases) is a valid proxy for an AD genetic study. After meta-analysing with published consortium data (n = 74,046 with 25,580 cases across the discovery and replication analyses), three new AD-associated loci (P < 5 × 10−8) are identified. These contain genes relevant for AD and neurodegeneration: ADAM10, BCKDK/KAT8 and ACE. Novel gene-based loci include drug targets such as VKORC1 (warfarin dose). We report evidence that the association of SNPs in the TOMM40 gene with AD is potentially mediated by both gene expression and DNA methylation in the prefrontal cortex. However, it is likely that multiple variants are affecting the trait and gene methylation/expression. Our discovered loci may help to elucidate the biological mechanisms underlying AD and, as they contain genes that are drug targets for other diseases and disorders, warrant further exploration for potential precision medicine applications. INTRODUCTION The genetic epidemiology of late-onset Alzheimer’s disease (LOAD) has advanced over the last decade1, with >20 independent loci associated with the disease in addition to APOE2. Presently, the largest meta-analytic genome-wide association study (GWAS) for LOAD employed a two-stage study design. First, 17,008 cases were compared to 37,154 controls. A total of 11,632 single-nucleotide polymorphisms (SNPs) with P < 1 × 10−3 from this meta-analysis were included in the second stage that compared 8,572 cases to 11,312 controls. A meta-analysis of the SNPs included in stages 1 and 2 was also performed3. One difficulty in traditional studies of AD is case ascertainment4—either directly for prevalent cases or indirectly through prospective cohort studies for incident cases. A recent GWAS study on a subset of the UK Biobank cohort used information from family history (parent or first-degree relative with AD or dementia) as a proxy-phenotype for the participants5. When meta-analysed with the GWAS summary data highlighted above3, four new loci were identified. The UK Biobank proxy-phenotype AD question, which is used here, does not incorporate biomarker data that are required for a clinical diagnosis. However, it is easy to administer at scale and we show that it has a near-unit genetic correlation with the AD results from the LOAD meta-analysis3, where many of the samples also lacked a confirmed diagnosis by biomarker levels or autopsy. In the present study, we related proxy-phenotype information on dementia (i.e., reporting a parent with Alzheimer’s dementia or dementia) to genetic data from 314,278 individuals from the UK Biobank cohort to identify new AD-associated loci. This sample includes individuals from the previous proxy-phenotype AD study by Liu et al.5 GWA studies were conducted separately for maternal and paternal AD due to a 1.7-fold difference in disease prevalence—9.6% and 5.5%, respectively. The summary statistics from these models were meta-analysed with those from the largest publicly available case–control study3. Sensitivity analyses showed that an overlap of controls in the maternal and paternal GWAS did not bias the results. Genetic correlation analysis showed the self-reported measure of parental AD to be an accurate proxy for clinical diagnosis, validating the global meta-analysis. In addition, we tested for causal evidence of our SNP–AD associations being mediated through gene expression and DNA methylation in the prefrontal cortex. SUBJECTS AND METHODS UK Biobank cohort UK Biobank data6 (http://www.ukbiobank.ac.uk) were collected on over 500,000 individuals aged between 37 and 73 years from across Great Britain (England, Wales and Scotland) at the study baseline (2006–2010), including health, cognitive and genetic data. The Research Ethics Committee (REC) granted ethical approval for the study—reference 11/NW/0382—and the current analysis was conducted under data application 10,279. Genotyping Genotyping details for the UK Biobank cohort have been reported previously7,8. Briefly, two custom genotyping arrays were utilised with 49,950 participants typed using the UK BiLEVE Axiom Array and 438,427 participants typed using the UK Biobank Axiom Array7,8. The released genotyped data contained 805,426 markers on 488,377 individuals. Imputed genotypes were supplied with the UK Biobank data with the Haplotype Reference Consortium (HRC) used as the imputation reference panel7. Downstream quality control steps conducted for the current analysis included removing (1) those with non-British ancestry based on both self-report and a principal components analysis, (2) outliers based on heterozygosity and missingness, (3) individuals with sex chromosome configurations that were neither XX nor XY, (4) individuals whose reported sex did not match inferred sex from their genetic data and (5) individuals with >10 putative third-degree relatives from the kinship table. This left a sample of 408,095 individuals. To remove the possibility of double contributions from sibs, whose parents will have the same AD status, we first considered a list of all participants with a relative (N = 131,790). A genetic relationship matrix was built for these individuals using GCTA-GRM9 and a relationship threshold of 0.025 was applied to exclude related individuals. After removing one person from each pair of related individuals, the sample size was 332,050. Quality control thresholds applied to the GWAS included: minor allele frequency >0.01, imputation quality score >0.3 and restriction to HRC-imputed SNPs, leaving a total of 7,795,605 SNPs for the GWAS. Phenotypes Family history of Alzheimer’s disease was ascertained via self-report. Participants were asked “Has/did your father ever suffer from Alzheimer’s disease/dementia?” and “Has/did your mother ever suffer from Alzheimer’s disease/dementia?” Self-report data from the initial assessment visit (2006–2010), the first repeat assessment visit (2012–2013) and the imaging visit (2014+) were aggregated with exclusions made for participants whose parents were: aged under 60 years; dead before reaching age 60 years; without age information. After merging with the genetic data, this left 27,696 cases of maternal AD with 260,980 controls, and 14,338 cases of paternal AD with 245,941 controls. There were 314,278 instances where AD information was available on at least one parent. Given the expected difference in disease prevalence due to sex differences in longevity—AD prevalence was 1.7-fold higher in mothers compared to fathers—GWA studies were performed separately for maternal and paternal AD. Genome-wide association study The GWA studies were conducted using BGENIE7. The outcome variable was the residuals from a linear regression model of maternal or paternal AD on age of parent at death or at time of the offspring’s self-report, assessment centre, genotype batch, array and 40 genetic principal components. The predictor variable was the autosomal SNP and an additive model was considered. The GWAS linear regression coefficients were converted to odds ratios using observed sample prevalences of 0.096 and 0.055 for maternal and paternal AD, respectively10. Subsequently, the log-odds were multiplied by two so that the effect sizes are reported on the same scale as a traditional case–control design5. Briefly, the conversion to odds ratios uses the following equation, derived in Lloyd-Jones et al.10, where k = disease prevalence, p =